Cargando…

DKK-1 in prostate cancer diagnosis and follow up

BACKGROUND: Dickoppf-1 (DKK-1) is a negative regulator of bone formation with tumorigenic potential. The up-regulation of DKK-1 is an early event in prostate cancer (PCa) development, thus we investigated its role as a marker in the diagnosis and prognosis of PCa. METHODS: We retrospectively enrolle...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Amelio, Patrizia, Roato, Ilaria, Oderda, Marco, Soria, Francesco, Zitella, Andrea, Ferracini, Riccardo, Mengozzi, Giulio, Gontero, Paolo, Isaia, Giovanni Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3976154/
https://www.ncbi.nlm.nih.gov/pubmed/24655661
http://dx.doi.org/10.1186/1472-6890-14-11
_version_ 1782310247829864448
author D’Amelio, Patrizia
Roato, Ilaria
Oderda, Marco
Soria, Francesco
Zitella, Andrea
Ferracini, Riccardo
Mengozzi, Giulio
Gontero, Paolo
Isaia, Giovanni Carlo
author_facet D’Amelio, Patrizia
Roato, Ilaria
Oderda, Marco
Soria, Francesco
Zitella, Andrea
Ferracini, Riccardo
Mengozzi, Giulio
Gontero, Paolo
Isaia, Giovanni Carlo
author_sort D’Amelio, Patrizia
collection PubMed
description BACKGROUND: Dickoppf-1 (DKK-1) is a negative regulator of bone formation with tumorigenic potential. The up-regulation of DKK-1 is an early event in prostate cancer (PCa) development, thus we investigated its role as a marker in the diagnosis and prognosis of PCa. METHODS: We retrospectively enrolled 159 patients who underwent prostate biopsy, either for elevated PSA or suspect digital rectal examination, between 2003 and 2010. During the biopsy, one serum sample was collected from all patients; PSA and DKK-1 were measured by ELISA technique. Amongst the biopsy of 159 patients 75 were affected by PCa and 84 were not the mean period of follow-up for these patients was 5 years; a new biopsy was performed in case of PCa suspicion. RESULTS: PSA performed better than DKK-1 in detecting PCa (0.63 vs 0.51 respectively). Differently from PSA DKK-1 was significantly higher in patients who developed PCa during follow-up than in cancer-free ones, thus DKK-1 performed better than PSA in detecting these patients (0.67 vs 0.55). DKK-1 was significantly lower in patients with bone metastases, whereas PSA was not significantly different in patients with different outcomes. CONCLUSIONS: DKK-1 might be predictive for patients negative at first biopsy who will develop PCa and in the prognosis of bone metastases. It performed worse than PSA in the early diagnosis of Pca.
format Online
Article
Text
id pubmed-3976154
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39761542014-04-05 DKK-1 in prostate cancer diagnosis and follow up D’Amelio, Patrizia Roato, Ilaria Oderda, Marco Soria, Francesco Zitella, Andrea Ferracini, Riccardo Mengozzi, Giulio Gontero, Paolo Isaia, Giovanni Carlo BMC Clin Pathol Research Article BACKGROUND: Dickoppf-1 (DKK-1) is a negative regulator of bone formation with tumorigenic potential. The up-regulation of DKK-1 is an early event in prostate cancer (PCa) development, thus we investigated its role as a marker in the diagnosis and prognosis of PCa. METHODS: We retrospectively enrolled 159 patients who underwent prostate biopsy, either for elevated PSA or suspect digital rectal examination, between 2003 and 2010. During the biopsy, one serum sample was collected from all patients; PSA and DKK-1 were measured by ELISA technique. Amongst the biopsy of 159 patients 75 were affected by PCa and 84 were not the mean period of follow-up for these patients was 5 years; a new biopsy was performed in case of PCa suspicion. RESULTS: PSA performed better than DKK-1 in detecting PCa (0.63 vs 0.51 respectively). Differently from PSA DKK-1 was significantly higher in patients who developed PCa during follow-up than in cancer-free ones, thus DKK-1 performed better than PSA in detecting these patients (0.67 vs 0.55). DKK-1 was significantly lower in patients with bone metastases, whereas PSA was not significantly different in patients with different outcomes. CONCLUSIONS: DKK-1 might be predictive for patients negative at first biopsy who will develop PCa and in the prognosis of bone metastases. It performed worse than PSA in the early diagnosis of Pca. BioMed Central 2014-03-21 /pmc/articles/PMC3976154/ /pubmed/24655661 http://dx.doi.org/10.1186/1472-6890-14-11 Text en Copyright © 2014 D’Amelio et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
spellingShingle Research Article
D’Amelio, Patrizia
Roato, Ilaria
Oderda, Marco
Soria, Francesco
Zitella, Andrea
Ferracini, Riccardo
Mengozzi, Giulio
Gontero, Paolo
Isaia, Giovanni Carlo
DKK-1 in prostate cancer diagnosis and follow up
title DKK-1 in prostate cancer diagnosis and follow up
title_full DKK-1 in prostate cancer diagnosis and follow up
title_fullStr DKK-1 in prostate cancer diagnosis and follow up
title_full_unstemmed DKK-1 in prostate cancer diagnosis and follow up
title_short DKK-1 in prostate cancer diagnosis and follow up
title_sort dkk-1 in prostate cancer diagnosis and follow up
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3976154/
https://www.ncbi.nlm.nih.gov/pubmed/24655661
http://dx.doi.org/10.1186/1472-6890-14-11
work_keys_str_mv AT dameliopatrizia dkk1inprostatecancerdiagnosisandfollowup
AT roatoilaria dkk1inprostatecancerdiagnosisandfollowup
AT oderdamarco dkk1inprostatecancerdiagnosisandfollowup
AT soriafrancesco dkk1inprostatecancerdiagnosisandfollowup
AT zitellaandrea dkk1inprostatecancerdiagnosisandfollowup
AT ferraciniriccardo dkk1inprostatecancerdiagnosisandfollowup
AT mengozzigiulio dkk1inprostatecancerdiagnosisandfollowup
AT gonteropaolo dkk1inprostatecancerdiagnosisandfollowup
AT isaiagiovannicarlo dkk1inprostatecancerdiagnosisandfollowup